American Association for Cancer Research
Browse
10780432ccr143127-sup-141958_0_supp_0_ns7fjt.docx (30.23 kB)

Supplementary Table S1 from CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We Now?

Download (30.23 kB)
journal contribution
posted on 2023-03-31, 18:42 authored by Isabelle Gingras, Christine Desmedt, Michail Ignatiadis, Christos Sotiriou

Summary of the commercially available proliferation-based gene-signatures in breast cancer

History

ARTICLE ABSTRACT

Desmedt and colleagues published two articles, one in the June 1, 2007 issue, and the other in the August 15, 2008, issue of Clinical Cancer Research, that showed gene-expression signatures to be proliferation driven and time dependent, with their prognostic power decreasing with increasing follow-up years. Moreover, the articles showed that immune response is a crucial determinant of prognosis in the HER2-positive and estrogen receptor–negative/HER2-negative subtypes, providing a rationale to further explore the role of the antitumor immune response in these breast cancer subtypes. Clin Cancer Res; 21(21); 4743–6. ©2015 AACR.See related articles by Desmedt et al., Clin Cancer Res 2007;13(11) June 1, 2007;3207–14 and Desmedt et al., Clin Cancer Res 2008;14(16) August 15, 2008;5158–65.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC